CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash
Globe Newswire•29/07/2026•22:51 ET
0
Whiz Insights
SAN FRANCISCO, July 29, 2026 (GLOBE NEWSWIRE) -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now.
The national investor rights firm has opened an investigation into whether Capricor misled investors about the efficacy and trial results of its lead product candidate, Deramiocel, intended for the treatment of Duchenne muscular dystrophy (DMD).
Get started
Create a free account to read the full story.